|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Suresh T, Lee L, Joshi J and Barta S: New
antibody approaches to lymphoma therapy. J Hematol Oncol. 7:582014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wu J, Fu J, Zhang M and Liu D:
Blinatumomab: A bispecific T cell engager (BiTE) antibody against
CD19/CD3 for refractory acute lymphoid leukemia. J Hematol Oncol.
8:1042015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nwabo Kamdje AH and Krampera M: Notch
signaling in acute lymphoblastic leukemia: Any role for stromal
microenvironment. Blood. 118:6506–6514. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Burger JA, Ghia P, Rosenwald A and
Caligaris-Cappio F: The microenvironment in mature B-cell
malignancies: A target for new treatment strategies. Blood.
114:3367–3375. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sun Z, Wang S and Zhao RC: The roles of
mesenchymal stem cells in tumor inflammatory microenvironment. J
Hematol Oncol. 7:142014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ding W, Nowakowski GS, Knox TR, Boysen JC,
Maas ML, Schwager SM, Wu W, Wellik LE, Dietz AB, Ghosh AK, et al:
Bi-directional activation between mesenchymal stem cells and CLL
B-cells: Implication for CLL disease progression. Br J Haematol.
147:471–483. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vlad A, Deglesne PA, Letestu R,
Saint-Georges S, Chevallier N, Baran-Marszak F, Varin-Blank N,
Ajchenbaum-Cymbalista F and Ledoux D: Down-regulation of CXCR4 and
CD62L in chronic lymphocytic leukemia cells is triggered by B-cell
receptor ligation and associated with progressive disease. Cancer
Res. 69:6387–6395. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang L, Lawrence MS, Wan Y, Stojanov P,
Sougnez C, Stevenson K, Werner L, Sivachenko A, DeLuca DS, Zhang L,
et al: SF3B1 and other novel cancer genes in chronic lymphocytic
leukemia. N Engl J Med. 365:2497–2506. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xu ZS, Zhang JS, Zhang JY, Wu SQ, Xiong
DL, Chen HJ, Chen ZZ and Zhan R: Constitutive activation of NF-kB
signaling by NOTCH1 mutation in chronic lymphocytic leukemia. Oncol
Rep. 33:1609–1614. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ross J, Mavoungou L, Bresenick EH and
Milot E: GATA-1 utilizes lkaros and polycomb repressive complex 2
to suppress Hes-1 and to promote erythropoiesis. Mol Cell Biol.
32:3624–3638. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hasslen SR, Burns AR, Simon SL, Smith CW,
Starr K, Barclay AN, Michie SA, Nelson RD and Erlandsen SL:
Preservation of spatial organization and antigenicity of leukocyte
surface molecules by aldehyde fixation: Flow cytometry and
high-resolution FESEM studies of CD62L, CD11b and Thy-1. J
Histochem Cytochem. 44:1115–1122. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chomozynski P and Sacchi N: Single step
method of RNA isolation by acid guanidinium thiocyanate phenol
chloroform extraction. Anal Biochem. 162:156–159. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cai MY, Hou JH, Rao HL, Luo RZ, Li M, Pei
XQ, Lin MC, Guan XY, Kung HF, Zeng YX and Xie D: High expression of
H3K27me3 in human hepatocellular carcinomas correlates closely with
vascular invasion and predicts worse worse prognosis in patients.
Mol Med. 17:12–20. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kikuchi J, Koyama D, Wada T, Izumi T,
Hofgaard PO, Bogen B and Furukawa Y: Phosphorylation-mediated EZH2
inactivation promotes drug resistance in multiple myeloma. J Clin
Invest. 125:4375–4390. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Amin S, Walsh M, Wilson C, Parker AE,
Oscier D, Willmore E, Mann D and Mann J: Cross-talk between DNA
methylation and active histone modifications regulates aberrant
expression of ZAP70 in CLL. J Cell Mol Med. 16:2074–2084. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Moshaver B, van der Pol MA, Westra AH,
Ossenkoppele GJ, Zweegman S and Schuurhuis GJ: Chemotherapeutic
treatment of bone marrow stromal cells strongly affects their
protective effect acute myeloid leukemia cell survival. Leuk
Lymphoma. 49:134–148. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lagneaux L, Delforge A, Bron D, De Bruyn C
and Stryckmans P: Chronic lymphocytic leukemic B cells are rescued
from apoptosis by contact with normal bone marrow stromal cells.
Blood. 91:2387–2396. 1998.PubMed/NCBI
|
|
19
|
Shimakura Y, Kawada H, Ando K, Sato T,
Nakamura Y, Tsuji T, Kato S and Hotta T: Murine stromal cell line
HESS-5 maintains reconstituting ability of ex vivo-generated
hematopoietic stem cells from human bone marrow and
cytokine-mobilized peripheral blood. Stem Cells. 18:183–189. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Roberts RA, Spooncer E, Parkinson EK, Lord
BI, Allen TD and Dexter TM: Metabolically inactive 3T3 cells can
substitute for marrow stromal cells to promote the proliferation
and development of multipotent hematopoietic stem cells. J Cell
Physiol. 132:203–214. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jiang H, Sugimoto K, Sawada H, Takashita
E, Tohma M, Gonda H and Mori KJ: Mutual education between
hematopoietic cells and bone marrow stromal cells through direct
cell-to-cell contact: Factors that determine the growth of bone
marrow stroma-dependent leukemic (HB-1) cells. Blood. 92:834–841.
1998.PubMed/NCBI
|
|
22
|
Smith AD, Roda D and Yap TA: Strategies
for modern biomarker and drug development in oncology. J Hematol
Oncol. 7:702014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ma S, Shi Y, Pang Y, Dong F, Cheng H, Hao
S, Xu J, Zhu X, Yuan W, Cheng T and Zheng G: Notch1-induced T cell
leukemia can be potentiated by microenvironmental cues in the
spleen. J Hematol Oncol. 7:712014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fabbri G, Rasi S, Rossi D, Trifonov V,
Khiabanian H, Ma J, Grunn A, Fangazio M, Capello D, Monti S, et al:
Analysis of the chronic lymphocytic leukemia coding genome: Role of
NOTCH1 mutational activation. J Exp Med. 208:1389–1401. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Balatti V, Bottoni A, Palamarchuk A, Alder
H, Rassenti LZ, Kipps TJ, Pekarsky Y and Croce CM: NOTCH1 mutations
in CLL associated with trisomy 12. Blood. 119:329–331. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xu Z, Zhang J, Wu S, Zheng Z, Chen Z and
Zhan R: Younger patients with chronic lymphocytic leukemia benefit
from rituximab treatment: A single center study in China. Oncol
Lett. 5:1266–1272. 2013.PubMed/NCBI
|
|
27
|
Fabris S, Bollati V, Agnelli L, Morabito
F, Motta V, Cutrona G, Matis S, Grazia Recchia A, Gigliotti V,
Gentile M, et al: Biological and clinical relevance of quantitative
global methylation of repetitive DNA sequences in chronic
lymphocytic leukemia. Epigenetics. 6:188–194. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Martín-Subero JI, Kreuz M, Bibikova M,
Bentink S, Ammerpohl O, Wickham-Garcia E, Rosolowski M, Richter J,
Lopez-Serra L, Ballestar E, et al: New insights into the biology
and origin of mature aggressive B-cell lymphomas by combined
epigenomic, genomic, and transcriptional profiling. Blood.
113:2488–2497. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lu Q, Lin X, Feng J, Zhao X, Gallagher R,
Lee YM, Chiao JW and Liu DL: Phenylhexyl isothiocyanate has dual
function as histone deacetylase inhibitor and hypomethylating agent
and can inhibit myeloma cell growth by targeting critical pathways.
J Hematol Oncol. 1:62008. View Article : Google Scholar : PubMed/NCBI
|
